Evaluation of detemir in diabetic cats managed with a protocol for intensive blood glucose control

J Feline Med Surg. 2012 Aug;14(8):566-72. doi: 10.1177/1098612X12446211. Epub 2012 May 2.


The aim of this study was to report outcomes using detemir and a protocol aimed at intensive blood glucose control with home monitoring in diabetic cats, and to compare the results with a previous study using the same protocol with glargine. Eighteen cats diagnosed with diabetes and previously treated with other insulins were included in the study. Data was provided by owners who joined the online German Diabetes-Katzen Forum. The overall remission rate was 67%. For cats that began the protocol before or after 6 months of diagnosis, remission rates were 81% and 42%, respectively (P = 0.14). No significant differences were identified between the outcomes for the glargine and detemir studies, with the exception of three possibly interrelated factors: a slightly older median age of the detemir cohort at diabetes diagnosis, a higher rate of chronic renal disease in the detemir cohort and lower maximal dose for insulin detemir.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Animals
  • Blood Glucose Self-Monitoring / veterinary
  • Cat Diseases / blood
  • Cat Diseases / drug therapy*
  • Cats
  • Cohort Studies
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 1 / veterinary*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / veterinary*
  • Dose-Response Relationship, Drug
  • Female
  • Hypoglycemic Agents / therapeutic use*
  • Insulin Detemir
  • Insulin Glargine
  • Insulin, Long-Acting / therapeutic use*
  • Male
  • Treatment Outcome


  • Hypoglycemic Agents
  • Insulin, Long-Acting
  • Insulin Glargine
  • Insulin Detemir